Nasdaq - Delayed Quote
USD
Eventide Healthcare & Life Sciences C (ETCHX)
45.52
-0.83
(-1.79%)
At close: 8:01:07 PM EST
Performance Overview
| Morningstar Return Rating | -- |
| YTD Return | 3.20% |
|---|---|
| 5y Average Return | 3.04% |
| Number of Years Up | 8 |
| Number of Years Down | 5 |
| Best 1Y Total Return (Oct 29, 2026) | 60.62% |
| Worst 1Y Total Return (Oct 29, 2026) | -- |
| Best 3Y Total Return | 60.62% |
| Worst 3Y Total Return | -10.28% |
Trailing Returns (%) Vs. Benchmarks
Monthly Total Returns
ETCHX
Category
- YTD
- 4.72%
- 7.95%
- 1-Month
- -7.05%
- 4.81%
- 3-Month
- -6.22%
- 7.18%
- 1-Year
- 31.47%
- 30.16%
- 3-Year
- 17.02%
- 16.10%
- 5-Year
- 3.54%
- 15.71%
- 10-Year
- 11.08%
- 15.27%
- Last Bull Market
- 59.83%
- 23.06%
- Last Bear Market
- -15.12%
- -13.88%
Annual Total Return (%) History
Year
ETCHX
Category
Past Quarterly Returns
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
|
2026
|
-4.96% | 17.49% | -6.22% | -- |
|
2025
|
-7.28% | 9.89% | 21.28% | 25.55% |
|
2024
|
4.47% | -12.26% | 6.71% | -9.02% |
|
2023
|
-1.87% | 14.62% | -11.86% | 10.86% |
|
2022
|
-23.42% | -15.12% | 13.60% | 7.79% |
|
2021
|
-7.79% | -8.49% | 4.00% | -5.89% |
|
2020
|
-23.83% | 37.31% | 2.05% | 27.11% |
|
2019
|
34.30% | -1.06% | -19.05% | 46.09% |
|
2018
|
4.54% | 14.60% | 9.38% | -24.56% |
|
2017
|
12.68% | 3.67% | 18.21% | 4.56% |
Rank in Category (By Total Return)
| YTD | 77 |
| 1-Month | 93 |
|---|---|
| 3-Month | 94 |
| 1-Year | 38 |
| 3-Year | 36 |
| 5-Year | 67 |
Load Adjusted Returns
| 1-Year | 30.47% |
| 3-Year | 17.02% |
|---|---|
| 5-Year | 3.54% |
| 10-Year | 11.08% |
Performance & Risk
| YTD Return | 3.20% |
| 5y Average Return | 3.04% |
| Rank in Category (ytd) | 77 |
| % Rank in Category (ytd) | -- |
| Beta (5Y Monthly) | 1.03 |
| Morningstar Risk Rating |
Fund Overview
| Category | Health |
| Fund Family | Eventide Funds |
| Net Assets | 1.65B |
| YTD Return | 4.72% |
| Yield | 0.00% |
| Morningstar Rating | |
| Inception Date | Dec 27, 2012 |
Fund Summary
Under normal market conditions, the fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.
